In total, income from Biocon’s biologics division was down 15% for the quarter (compared with the same period for the company’s prior financial year), despite the fact that product sales grew 16% year over year, with increased sales of insulins and biosimilar antibodies. The company’s total net profits declined by 46%.
On January 24, Biocon, the India-based biosimilar developer behind the recently FDA-approved trastuzumab biosimilar, Ogivri, reported its consolidated financial results for the third quarter of its fiscal year (ending on December 31, 2017).
Biocon’s chairperson and managing director, Kiran Mazumdar-Shaw, highlighted the company’s joint success with partner Mylan in gaining the FDA’s approval for Ogivri, saying that the company had reached a “major milestone” in gaining clearance for its Herceptin challenger in the United States’ market.
Yet approval of Ogivri came at a price to Biocon; after the French National Agency for Medicines and Health Products Safety found that the biosimilar developer had failed to comply with good manufacturing practices in the production of 3 biosimilar products (including trastuzumab), Biocon was forced to undergo a re-inspection of its fill-finish plant after addressing 35 problems related to drug product manufacturing and quality control operations.
The activities undertaken to requalify the facility caused production disruptions and supply constraints for some products, leading to declining sales.
Not only did the need to undertake the re-inspection apparently delay FDA approval of Ogivri, but it also, according to Biocon’s statement, “…led to production disruption and supply constraints for some products, thereby impacting sales.”
Also negatively impacting Biocon’s overall financial picture were depreciation costs related to operations in its Malaysian facility. In total, income from Biocon’s biologics division was down 15% for the quarter (compared to the same period for the company’s prior financial year), despite the fact that product sales grew 16% year over year, with increased sales of insulins and biosimilar antibodies. The company’s total net profits declined by 46%.
Despite disappointing profits, Biocon sought to reassure investors about its biosimilar potential by highlighting its recently announced partnership with Sandoz for the development of a portfolio of biosimilars. “This collaboration addresses some of the long-term biosimilars opportunities beyond the near-term opportunities being addressed by our existing and continuing successful global partnership with Mylan,” said Biocon. “This new partnership is a significant milestone in Biocon's journey of developing high quality, affordable biologics that have the potential to benefit patients globally.”
The Economic Times reported that Biocon’s shares closed down 1.2% after the quarterly report was issued.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.